Tubeeckx, Michiel R. L. http://orcid.org/0000-0002-1337-0727
De Keulenaer, Gilles W. http://orcid.org/0000-0002-4238-4183
Heidbuchel, Hein http://orcid.org/0000-0001-9301-8127
Segers, Vincent F. M. http://orcid.org/0000-0001-7796-2222
Funding for this research was provided by:
Universiteit Antwerpen (PID36444)
Fonds Wetenschappelijk Onderzoek (1842219N, G021019N, G021420N)
VLIRUOS (20-VLIR-iBOF-027)
Article History
Received: 30 September 2023
Revised: 1 February 2024
Accepted: 2 February 2024
First Online: 12 March 2024
Declarations
:
: None of the authors has any personal conflicts of interest. MRLT, GWDK, and VFMS are acknowledged in a pending patent application without financial interest for their work on a Neuregulin-1 fusion protein to treat fibrosis and arrhythmia. This is unrelated to the content of this manuscript. HH received unconditional research support through the University of Hasselt or University of Antwerp from Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, Bracco Imaging Europe, Medtronic, Boston-Scientific, Biotronik, and St Jude Medical, all outside the scope of this work.